3 Health Care Stocks Dragging The Sector Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 13 points (0.1%) at 16,507 as of Monday, Aug. 4, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,334 issues advancing vs. 1,665 declining with 161 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the sector include Alere ( ALR), down 13.5%, Catamaran ( CTRX), down 3.1%, Taro Pharmaceutical Industries ( TARO), down 2.7%, ResMed ( RMD), down 1.9% and Teva Pharmaceutical Industries ( TEVA), down 1.7%. Top gainers within the sector include Amgen ( AMGN), up 1.1%, AstraZeneca ( AZN), up 1.0%, Gilead ( GILD), up 0.9%, Medtronic ( MDT), up 0.9% and Eli Lilly and ( LLY), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Endo International ( ENDP) is one of the companies pushing the Health Care sector lower today. As of noon trading, Endo International is down $1.60 (-2.4%) to $66.02 on light volume. Thus far, 632,690 shares of Endo International exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $65.94-$68.10 after having opened the day at $67.73 as compared to the previous trading day's close of $67.62.

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. Endo International has a market cap of $10.2 billion and is part of the drugs industry. Shares are up 0.2% year-to-date as of the close of trading on Friday. Currently there are 9 analysts that rate Endo International a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Endo International as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we find that net income has been generally deteriorating over time. Get the full Endo International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Alexion Pharmaceuticals ( ALXN) is down $0.98 (-0.6%) to $158.14 on light volume. Thus far, 402,376 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $157.22-$160.57 after having opened the day at $159.35 as compared to the previous trading day's close of $159.12.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $31.5 billion and is part of the drugs industry. Shares are up 19.7% year-to-date as of the close of trading on Friday. Currently there are 11 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Perrigo ( PRGO) is down $2.22 (-1.5%) to $149.37 on light volume. Thus far, 362,107 shares of Perrigo exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $148.33-$152.33 after having opened the day at $151.95 as compared to the previous trading day's close of $151.59.

Perrigo is buying Canam Care as of Jan 2012 for $36. Perrigo has a market cap of $20.1 billion and is part of the drugs industry. Shares are down 1.2% year-to-date as of the close of trading on Friday. Currently there are 12 analysts that rate Perrigo a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Perrigo as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Perrigo Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Facebook Sends Facial Recognition Notification in Error

Facebook Sends Facial Recognition Notification in Error

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists